What Does Frequency Therapeutics Do?

Total employees36
HeadquartersLexington
Founded2014

Frequency Therapeutics was a clinical-stage biotechnology company that aimed to develop a new class of regenerative medicine. Their primary research focused on activating progenitor cells within the body to repair or reverse damage from degenerative diseases, with a lead program targeting sensorineural hearing loss (SNHL). After its lead candidate FX-322 failed to meet primary endpoints in a Phase 2b study in early 2023, the company discontinued its hearing loss programs, underwent significant restructuring, and subsequently completed a reverse merger with Korro Bio in November 2023. The combined entity operates as Korro Bio. This information reflects Frequency Therapeutics as an entity prior to these conclusive events.

Where Is Frequency Therapeutics's Headquarters?

HQ Function

The headquarters served as the main center for the company's research and development activities, clinical trial management, and corporate operations.

Notable Features:

Situated within the Hayden Research Campus, the facility likely comprised modern laboratory spaces, R&D infrastructure, and corporate offices suitable for a clinical-stage biotech company.

Work Culture:

Prior to its strategic pivot and merger, Frequency Therapeutics likely fostered a science-driven, innovative, and collaborative work environment focused on translational research and addressing unmet medical needs. The culture would have experienced significant shifts during the 2023 restructuring and merger process.

HQ Significance:

Its location in Lexington provided strategic proximity to a dense ecosystem of academic institutions, research talent, and other life science companies, facilitating collaborations and recruitment.

Values Reflected in HQ: The choice of a well-equipped facility in a prominent biotech cluster underscored its commitment to scientific innovation and advancement in regenerative medicine (prior to program discontinuation).

Location:

Frequency Therapeutics' global activities were primarily centered around its clinical trial operations for its therapeutic candidates. These trials involved sites in the United States and select countries in Europe. The company did not maintain significant independent international offices for corporate or R&D functions, which were centralized at its U.S. headquarters.

Street Address:

75 Hayden Avenue

City:

Lexington

State/Province:

MA

Country:

USA

Where Else Does Frequency Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Frequency Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Frequency Therapeutics? Meet the Executive Team

As of April 2025, Frequency Therapeutics' leadership includes:

David L. Lucchino - Former Co-founder, President, and Chief Executive Officer
Chris Loose, Ph.D. - Former Co-founder and Chief Scientific Officer
Peter P. Pfreundschuh - Former Chief Financial Officer
Wendy Arnold - Former Chief People Officer
Carl P. LeBel, Ph.D. - Former Chief Development Officer

Who's Investing in Frequency Therapeutics?

Frequency Therapeutics has been backed by several prominent investors over the years, including:

Perceptive Advisors
Polaris Partners
RTW Investments, LP
Atlas Venture
GV (Google Ventures)
Alexandria Venture Investments
CoVision Media, L.P.
Deerfield Management
Federated Hermes Kaufmann Funds
Mizuho Securities Principal Investment

What Leadership Changes Has Frequency Therapeutics Seen Recently?

Hire0
Exits5

The period leading up to and including Frequency Therapeutics' merger with Korro Bio in November 2023 saw a complete transition of its executive leadership. Following the merger, the Frequency Therapeutics executive team departed, and the combined company proceeded under Korro Bio's leadership. This was preceded by strategic restructuring in early 2023.

Departures

David L. Lucchino, Departed his role as CEO in conjunction with the Korro Bio merger.
Chris Loose, Ph.D., Departed his role as CSO in conjunction with the Korro Bio merger.
Peter P. Pfreundschuh, Departed his role as CFO in conjunction with the Korro Bio merger.
Wendy Arnold, Departed her role as CPO in conjunction with the Korro Bio merger.
Carl P. LeBel, Ph.D., Departed his role as CDO in conjunction with the Korro Bio merger.

What Technology (Tech Stack) Is Used byFrequency Therapeutics?

Discover the tools Frequency Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Frequency Therapeutics Email Formats and Examples

Prior to its merger and operational cessation, Frequency Therapeutics likely used standard corporate email address formats. A common pattern in the industry is [first_initial][last]@[companydomain.com].

[first_initial][last]@frequencytx.com

Format

jdoe@frequencytx.com

Example

0%

Success rate

What's the Latest News About Frequency Therapeutics?

Korro Bio / PR NewswireNovember 14, 2023

Korro Bio and Frequency Therapeutics Announce Closing of Merger

Korro Bio, Inc. and Frequency Therapeutics, Inc. announced the successful completion of their merger. The combined company now operates as Korro Bio, Inc., trading on Nasdaq under 'KRRO', and will focus on advancing Korro's RNA editing pipeline....more

Frequency Therapeutics / GlobeNewswireJuly 17, 2023

Frequency Therapeutics and Korro Bio to Merge to Create a Leading Company in RNA Editing

Frequency Therapeutics entered into a definitive merger agreement with Korro Bio. The transaction aimed to combine Frequency's resources with Korro's RNA editing platform, with the new entity to operate as Korro Bio....more

Frequency Therapeutics / GlobeNewswireFebruary 13, 2023

Frequency Therapeutics Announces Discontinuation of Hearing Loss Program After Phase 2b Study Results

Frequency Therapeutics reported that its FX-322 candidate for acquired sensorineural hearing loss did not meet its primary efficacy endpoint in a Phase 2b study. As a result, the company discontinued the hearing loss program and initiated a strategic review, including workforce reductions....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Frequency Therapeutics, are just a search away.